News & Updates

The KRAS^G12C inhibitors, adagrasib and sotorasib, have shown promising antitumour activity in patients with heavily pretreated metastatic colorectal cancer (mCRC) and metastatic pancreatic cancer, respectively.

Pancreatic cancer may be identified early if assessment will be steered towards the point of recent hyperglycaemia based on elevated HbA1c, suggests a retrospective cohort study, noting that such early detection may then improve survival in cancer patients.

Proton pump inhibitor (PPI) therapy does not appear to put individuals who require gastric acid suppression at increased risk of gastric cancer, according to a study.

In Malaysia, breast, colorectal, and lung cancers account for approximately half of all reported cancer cases. In order of prevalence, breast cancer tops the list, followed by colorectal, lung, nasopharyngeal, and liver cancers. [Available at https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf Accessed on 27 October 2022]

The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.